EAST RUTHERFORD, N.J., May 15 /PRNewswire-FirstCall/ -- Cambrex (NYSE:
CBM), a leading life sciences company, announced today that the Board of
Directors appointed Steven M. Klosk, President and Chief Executive Officer
and a member of the Cambrex Corporation Board of Directors effective May
14, 2008. James A. Mack, President and Chief Executive Officer since 1995
and Chairman since 1999, has announced he will step down. The Company will
separate the positions of Board Chairman and CEO and John R. Miller,
currently lead director, will assume the position of Non-Executive Chairman
of the Board. Mr. Mack will remain a Board member and advisor until his
retirement on June 30, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
Mr. Klosk, 51, joined Cambrex in October 1992 as Vice
President-Administration. He was appointed Executive Vice President,
Administration in October 1996, and was promoted to the position of
Executive Vice President and Chief Operating Officer for Cambrex Pharma and
BioPharmaceutical Business Unit in October 2003. In January 2005 Mr. Klosk
assumed direct responsibility for the BioPharmaceutical Business Unit as
Chief Operating Officer. In January 2007 he was appointed Executive Vice
President and Chief Operating Officer for the Corporation. He holds a
Bachelor of Science degree from Cornell University and a J. D. degree from
New York Law School.
"I have enjoyed my many years with Cambrex and now is the right time to
turn the Company over to new leadership. I am confident that with his many
years with Cambrex, Steve will ably continue the pattern of growth that is
so much a part of the Company," commented Mr. Mack.
"I am excited about the opportunity to lead the Cambrex team as we
focus on our growth initiatives in proprietary products and polymeric drug
delivery, highly potent compounds, controlled substances and our growing
pipeline of new custom development products. In addition, we are well
positioned to leverage our recently completed facility near Milan, Italy to
support our leading position in generic active pharmaceutical ingredients,"
said Mr. Klosk. "I am extremely grateful to Jim for his many years of
outstanding service to Cambrex and for his personal mentorship."
About Cambrex
Cambrex provides products and services to accelerate the development
and commercialization of small molecule active pharmaceutical ingredients
("APIs"), advanced intermediates and other products for branded and generic
pharmaceuticals. The Company currently employs approximately 850 people
worldwide. For more information, please visit http://www.cambrex.com.
SOURCE Cambrex
 back to top
Related links:
http://www.cambrex.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/134219.html /
CONTACT:
Stephanie LaFiura, IR Associate, Cambrex,
+1-201-804-3037, stephanie.lafiura@cambrex.com
|
